TNF and enthesitis-related juvenile idiopathic arthritis: While studies mention that adalimumab is superior to etanercept for biologic-naive juvenile enthesitis-related arthritis (ERA) [5], our choice of anti-TNF inhibitor was mainly due to availability at the time of treatment.